Alexander Lefterov/Endpoints News
January 25, 2022 07:10 AM ESTUpdated 01:20 PM
R&D
In Focus

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

Jason Mast

Editor

Bob Seib­ert sat silent across from his daugh­ter at their fa­vorite Span­ish restau­rant near his home in Charleston Coun­ty, SC, their pael­la grow­ing cold as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times